Back to People

Connie Li

Senior Associate

617-999-9411

About

Connie is a Senior Associate on the healthcare team at F-Prime Capital. She works across the healthcare sub-sectors including Therapeutics, MedTech, and Healthcare IT and Services, and also closely with the Eight Roads Ventures China team to manage F-Prime’s existing and new investment efforts in China. Prior to joining F-Prime Capital, Connie was a Consultant with IQVIA in New York, where she advised biopharmaceutical companies on commercial, development, and portfolio strategy topics.

Connie received her B.S.E. in Bioengineering from the University of Pennsylvania.

  • Gyenno is a digital health company based in Shenzhen, China that is developing a holistic specialty care platform to improve diagnosis, disease management, and clinical research in Parkinson’s Disease and other CNS disorders. Lean more at www.gyenno.com/index-en.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Shenzhen, China

    • Year Invested

      2021

    • Team

      Chong Xu, Ph.D., Connie Li

  • K36 Therapeutics was established with the mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies. Its vision is to create breakthrough therapies for the unmet medical needs of cancer patients worldwide. Learn more at https://www.k36tx.com/.

  • KnowYourself is a digital health company that is focused on promoting mental wellness in China.

  • MediTrust Health is a provider of payment services for medical healthcare. The company is dedicated to helping patients solve their own medical payment problems through financial insurance, manage medical expenses more efficiently, and providing value to patients around medical finance, curative effect insurance, and drug benefits, helping patients manage their medical expenses. Learn more at www.meditrusthealth.com.

  • Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children’s medicines to provide Chinese children and families with high-quality and affordable treatment options

  • Skyline Therapeutics (formerly Geneception) is a fully-integrated gene and cell therapy based in Hangzhou and Shanghai, China.  Founded by F-Prime Capital, Eight Roads Ventures China and Lilly Asia Ventures in 2018, Skyline’s mission is to become a preeminent gene and cell therapy company, working to deliver world-class therapeutics for patients in China and globally.